Kite Pharma’s Post

Two subtypes of cutaneous T-cell lymphoma (#CTCL) - Mycosis Fungoides and Sézary Syndrome - manifest and spread in different ways, including within the blood. Learn more at https://bit.ly/3Z9CSnR #BloodCancerAwarenessMonth

Positive late-breaking data from the pivotal Phase 3 inMIND trial was presented at the American Society of Hematology Annual Meeting, evaluating a treatment for patients with relapsed or refractory follicular lymphoma (FL). Learn more. #News #ASH24 https://bit.ly/49u6NKO

FDA accepts supplemental BLA for Columvi (glofitamab) + chemotherapy combination for people with relapsed or refractory diffuse large B-cell lymphoma - Roche https://lnkd.in/g2gfkA-g

ALPHA3, a Pivotal Phase 2 Study of First-Line Consolidation with Cemacabtagene Ansegedleucel (Cema-Cel) in Patients with Large B-Cell Lymphoma and Minimal Residual Disease after Response to Standard Therapy - https://lnkd.in/gDkQdGR8

Small Bowel Lymphoma: Facts From "CT of Lymphoma: Involvement of the GI Tract - Part 1" View the full lecture here: https://lnkd.in/gKzpp8cz

We’re pleased to announce publication in The Lancet Haematology of data from the investigator-initiated Phase 2 clinical trial evaluating our CD19-targeted #antibodydrugconjugate in combination with rituximab for the treatment of r/r follicular lymphoma as presented at #ASH24. Learn more: https://lnkd.in/eKANnEtz

💫 ECHO Phase III trial 💫 🌟 CALQUENCE combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in the ECHO Phase III trial 👉 First BTK inhibitor to show favorable trend in overall survival vs. standard-of-care chemoimmunotherapy in this setting 🔗 https://buff.ly/3UnGBdK #OncEd #ONCOnews #OncoAlert

Evaluate targeted therapeutic options in relapsed/refractory follicular lymphoma with our on-demand webcast. Learn how to implement multidisciplinary team strategies and shared decision-making to select optimal treatment and support patients with R/R FL. Watch now: https://okt.to/iS7AJp

🚀 Discover Cutting-Edge Treatments: Delve into the role of 🧬 bispecific antibodies in R/R non-Hodgkin lymphoma. Sharpen your skills in administration, managing side effects, and integrating these therapies into care plans. Save Your Seat: http://ms.spr.ly/6048mogw8

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma https://lnkd.in/gjd3ZHwj